Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter
ABBOTT PARK, Ill., June 23 /PRNewswire-FirstCall/ -- Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting
Coronary Stent System f...
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Company Enrolls First Patient into SPIRIT PRIME Trial in the United States
ABBOTT PARK, Ill., June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation XIENCE PRIME(TM) E...
XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration
MENLO PARK, Calif., June 4 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that the Company received conditional approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) authorizing it to begin its pivotal clinical pro...
Better patient outcomes with drug eluting stents
Patients receiving drug eluting
stents (DES) stents coated with medication to prevent narrowing of the artery as part of an angioplasty had better outcomes one year later than patients with bare metal stents, according to a new study to be published in CMAJ http://www.cmaj.ca/press/080050.pdf...
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
ABBOTT PARK, Ill., Dec. 17 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT )
today announced the start of SPIRIT Small Vessel, a clinical trial evaluating
a 2.25 mm size of the XIENCE V(TM) Everolimus Eluting
Coronary Stent System.
The 2.25 mm stent system would offer physicians an option for treat...
Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
Japan Submission Includes Clinical Data Demonstrating Superiority of XIENCE V Compared to TAXUS(R) Drug Eluting
TOKYO, June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today
announced that it has submitted an application for Seizo Hanbai Shonin
(Marketing Authorization L...
Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
New 2.25 mm Diameter Stent Now Available in Europe, Asia and Latin America
ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- Abbott (NYSE:
ABT) announced today that it has received CE Mark (Conformite Europeene)
approval for a 2.25 mm version of its XIENCE(TM) V Everolimus Eluting
Devax Announces Completion of Enrollment of DIVERGE Trial of Novel Drug- Eluting Stent System for Bifurcation Lesions
- Five hundred patients treated with company's AXXESS(TM) System to date -
LAKE FOREST, Calif., Dec. 12 /PRNewswire/ -- Devax, Inc., a medical
device company focused on developing next generation products for
interventional cardiology, today announced that the Company has completed
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
ABBOTT PARK, Ill., Nov. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE:
ABT)announced today that the Circulatory System Devices Advisory Panel to
the U.S. Food and Drug Administration (FDA) recommended approval for the
XIENCE(TM) V Everolimus Eluting
Coronary Stent System. XIENCE V is a
Aeon Bioscience Continues Development of Drug Eluting Stents
BIRMINGHAM, Ala., Oct. 10 /PRNewswire-USNewswire/ -- Aeon Bioscience,
Inc. today announced the recent acquisition of one of its key
collaborators, Brookwood Pharmaceuticals, Inc. by SurModics, Inc., a major
development in its quest to develop improvements in drug-eluting stent
technology for t...
Eluting in Medical Technology
Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data
WARRENDALE, Pa., May 18 /PRNewswire/ -- MEDRAD Interventional(TM)/Possis(R) today announced that it has reached key milestones in bringing the Paccocath(R) Technology closer to market as an option for the over 14 million patients in the United States and Europe who suffer from Peripheral Arterial ...
Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms
NATICK, Mass. and ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE: BSX ) today welcomed three-year results from the
SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the
SPIRIT II and III Trials. SPIRIT II and SPIRIT III are pros...
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
ABBOTT PARK, Ill., March 24 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT ) today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company's fully bioabsorbable drug eluting
coronary stent. This second phase of the ABSORB clinic...
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Data Demonstrate Bioabsorbable Stent Is Absorbed Within Two Years, Leaving Behind Blood Vessels that Appear to Move and Function Similar to Untreated Vessels
ABBOTT PARK, Ill., March 12 /PRNewswire-FirstCall/ -- A comprehensive analysis published today in The Lancet , one of the world's le...
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
ABBOTT PARK, Ill., Jan. 26 /PRNewswire-FirstCall/ -- Data published online
today in Circulation from the SPIRIT III U.S. pivotal trial evaluating the
XIENCE V(TM) Everolimus Eluting
Coronary Stent System demonstrated that
Abbott's market-leading XIENCE V outperforms the TAXUS(R) Express2(TM)...
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
New Analysis of SPIRIT II and SPIRIT III Data Confirms Patients Treated
with XIENCE V Are at Lower Risk of Experiencing Death, a Heart Attack or a Repeat Procedure Compared to TAXUS(R) at Two Years
WASHINGTON, Oct. 13 /PRNewswire-FirstCall/ -- Data from an independent
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Patients Treated with XIENCE V in SPIRIT III Trial Experience Better
Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS
BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data
presented for the first time today f...
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
SPIRIT III Results Demonstrate Superior Reduction in In-Segment Late Loss,
Non-Inferiority in Target Vessel Failure and Low Rates of MACE with XIENCE V Compared to TAXUS
ABBOTT PARK, Ill., April 22 /PRNewswire-FirstCall/ -- A study published
in today's Journal of the A...
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
- New Data from SPIRIT II Show Continued Low Rates of MACE with XIENCE V -
CHICAGO, March 31 /PRNewswire-FirstCall/ -- Data presented today from
Abbott's SPIRIT II clinical trial demonstrated continued positive clinical
results for the XIENCE(TM) V Everolimus Eluting
Coronary Stent System out
Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
One-Year Data on First 30 Patients Enrolled in Ongoing Study Presented at TCT
WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today
announced continued positive results from ABSORB, the world's first
clinical trial evaluating the safety and pe...
Eluting in Medical Products
CoStar Paclitaxel-eluting Coronary Stent System
Description:...systems COSTAR paclitaxel stent. Radically different from conventional drug eluting
stents, the CONOR Medsystems stent is the first non-surface-coated drug eluting
stent designed to provide advanced drug delivery capabilities. CONOR Medsys...
Company:Biotronik GmbH & Co.
Selute® Picotip Atrial J
Description:... Steroid eluting
pacemaker leads with preformed J...
Description:... Steroid eluting
Sweet Picotip RX
Description:... Steroid eluting
Sweet Picotip® RX
Description:... Steroid eluting
Selute Picotip Atrial J
Description:... Selute Picotip Atrial-J steroid eluting
passive fixation lead...
Attain OTW Model 4194 Bi-Polar
Features:... Angled distal end designed for steerability and stable fixation in range of veins
designed to minimize threshold peaking
Exclusive tip seal designed to minimize blood ingress to the lead body, and designed to facilitate rep...
Attain™ OTW Left-heart Lead
Features:... Angled distal end designed for steerability and stable fixation in range of veins.
designed to minimize threshold peaking.
Exclusive tip seal designed to minimize blood ingress to the lead body, and designed to facilitate reposition...
Features:...r passage and positioning. The special designed flexible connectors and small bifurcation sleeve facilitate wrapping around the pacemaker. The steroid eluting
electrode provides lower acute and chronic pacing thresholds allowing low pacing output settings. Tip - center atrial rings: 15.5 cm....
Features:...eases the impedance to deliver energy most efficiently. The high impedance saves energy and extends the pacemaker longevity significantly. The steroid eluting
electrode provides low acute and chronic pacing thresholds, allowing low output programming. The small 6F lead body allows easier passage and position...
Eluting in Medical Dictionary
...y balloon angioplasty - series ... Coronary heart disease (CHD) (angioplasty and stent placement - heart) ... DESCRIPTION ... Home " Drug eluting
Stent Center " Overview ... The concept of the stent grew directly out of interventional cardiologists' ... A stent is a small mesh-wire tub...
Eluting in Biological News
The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
ABBOTT PARK, Ill., March 13, 2008 Data published today in The Lancet from ABSORB, the worlds first clinical trial of a fully bioabsorbable drug eluting
stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-t...
Supercomputing equipment to advance the frontiers of computational biology
... develop simulations for prototyping medical devices in "virtual patients," with potential applications in targeted drug delivery systems such as drug eluting
stents, transdermal patches, and inhalers.
To be successful, these simulations must run efficiently and effectively on the latest generation of h...
Eluting in Biological Technology
Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
Fourth Innovation Award for Abbott in Six Years Recognizes Breakthrough Treatment for the Most Common Form of Heart Disease
ABBOTT PARK, Ill., Oct. 28 /PRNewswire/ -- Abbott today announced it
has received a 2008 Chicago Innovation Award for its XIENCE V(TM)
Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
Zero Incidence of Late Stent Thrombosis Reported in CUSTOM I, II, and III Trials
WASHINGTON and MENLO PARK, Calif., Oct. 13 /PRNewswire-FirstCall/ --
XTENT, Inc. (Nasdaq: XTNT ) today announced positive long-term follow-up
data from the CUSTOM I, II and III clin...
Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
XIENCE V USA Study to Evaluate Treatment of Coronary Artery Disease Patients in Real-World Setting
ABBOTT PARK, Ill., July 9 /PRNewswire-FirstCall/ -- Abbott today
announced the start of the XIENCE V(TM) USA post-approval study, with six
hospital centers already recruitin...
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
XIENCE V, Only Drug Eluting
Stent to Demonstrate Superiority Over
Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease
ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today
announced that the U.S. Food a...
The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Future Generation Treatment from Abbott Shows No Thrombosis, Low MACE Rates Out to One Year in Preliminary Clinical Study of Thirty Patients
ABBOTT PARK, Ill., March 13 /PRNewswire-FirstCall/ -- Data published
today in The Lancet from ABSORB, the world's first clinical trial of a
InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
...hanism with the help of the novel micron-level net for next
generation drug eluting
stents. InspireMD intends to pursue applications of
this technology both for bare metal and drug eluting
stents in coronary,
carotid and peripheral artery procedures.
OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
...up compared with patients receiving the Taxus drug eluting
stent, but there were no stent thrombosis events a...gies to address the shortcomings with current drug eluting
stents (DES), namely the safety concerns associate...gress with the next generation of pro-healing drug eluting
stent (SES) featuring a combination of endothelial...
XTENT to Retain Investment Bank to Pursue Strategic Alternatives
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting
stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause...
Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
Forms Alliance to Jointly Develop Drug eluting
RALEIGH, N.C., Jan. 12 /PRNe...ies also entered into an agreement to develop Drug eluting
Balloon (DEB) products for cardiovascular applicat...es Cardiac Stents of various types, including Drug eluting
Coronary stents used in critical cardiac care. In...
Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President
...g Worldwide Vice President of Sales and Marketing at Cordis
Corporation where he oversaw the cardiovascular business including the market
leading drug eluting
stent, CYPHER (TM). Mr. Pinon received a bachelor's
degree in biology from the University of Oregon .
Terumo Heart, Inc. is a U.S. subsidiar...
Eluting in Biological Products
Autotrace SPE Workstation from Caliper Life Sciences
Description:... The unit can process up to six samples in parallel, automatically conditioning, washing, and eluting
SPE cartridges with a choice of up to five reagents. The unit also segregates aqueous and solvent waste using separate waste lines for efficient, cost...
Company:Caliper Life Sciences
AccuSpot from Shimadzu Biotech
Description:...be performed with a higher degree of precision and with greater sequence coverage. AccuSpot technology Designed for on-line collection of fractions eluting
from Capillary/Nano LC. Supports micro-fractionaction on MALDI-TOF/MS targets, for 96 or 384 well plates. Multiple plates can be spotted continuou...
Eluting in Biological Definition
...reverse" phase (RP-HPLC) stationary phases are hydrophobic. On an RP-HPLC column, then, hydrophobic analytes would tend to be retained on the column, eluting
more readily as the proportion of the hydrophobic component of the mobile phase is increased. RP-HPLC has lower resolution than GC.